Skip to main content
Journal cover image

Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction.

Publication ,  Journal Article
Wang, TY; Chen, AY; Alexander, KP; Ohman, EM; Gibler, WB; Peterson, ED; Roe, MT
Published in: Am J Med
September 2008

BACKGROUND: Although the use of heparin with fibrinolytics is associated with more rapid ST-segment resolution and increased infarct-related artery patency among patients with ST-segment elevation myocardial infarction (STEMI), its associated increase in bleeding risk is well documented and might be augmented by excess heparin dosing. METHODS: We sought to characterize the incidence and associated bleeding risk of excess heparin dosing among patients with STEMI treated with fibrinolysis who were enrolled in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines initiative. Excess dosing was defined as a bolus more than 60 U/kg or an infusion more than 12 U/kg/h per American College of Cardiology/American Heart Association guidelines and was further stratified into major and mild excess (major defined as a bolus>70 U/kg or infusion >15 U/kg/h). RESULTS: Among 964 fibrinolytic-treated patients with STEMI, 758 (79%) received adjunctive unfractionated heparin therapy. Of these, 368 patients (49%) received excess dosing of unfractionated heparin and 137 patients (18%) received major excess heparin dosing. Factors significantly associated with excess dosing included low body weight and female sex. Patients who received major excess dosing had higher unadjusted rates of major bleeding (19.2% vs 12.4%, P=.004) and transfusion (13.5% vs 4.7%, P=.0002) than patients without excess dosing. After adjustment, a trend persisted for the association with higher transfusion risk (odds ratio 1.39 [0.61-3.14]). CONCLUSION: Approximately half of fibrinolytic-treated patients with STEMI in contemporary practice received an excess dose of unfractionated heparin. Careful attention to dosing is needed to limit the compounded bleeding risk when heparin is added to fibrinolytic therapy.

Duke Scholars

Published In

Am J Med

DOI

EISSN

1555-7162

Publication Date

September 2008

Volume

121

Issue

9

Start / End Page

805 / 810

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Risk
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Logistic Models
  • Incidence
  • Humans
  • Heparin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, T. Y., Chen, A. Y., Alexander, K. P., Ohman, E. M., Gibler, W. B., Peterson, E. D., & Roe, M. T. (2008). Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. Am J Med, 121(9), 805–810. https://doi.org/10.1016/j.amjmed.2008.04.023
Wang, Tracy Y., Anita Y. Chen, Karen P. Alexander, E Magnus Ohman, W Brian Gibler, Eric D. Peterson, and Matthew T. Roe. “Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction.Am J Med 121, no. 9 (September 2008): 805–10. https://doi.org/10.1016/j.amjmed.2008.04.023.
Wang TY, Chen AY, Alexander KP, Ohman EM, Gibler WB, Peterson ED, et al. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. Am J Med. 2008 Sep;121(9):805–10.
Wang, Tracy Y., et al. “Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction.Am J Med, vol. 121, no. 9, Sept. 2008, pp. 805–10. Pubmed, doi:10.1016/j.amjmed.2008.04.023.
Wang TY, Chen AY, Alexander KP, Ohman EM, Gibler WB, Peterson ED, Roe MT. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. Am J Med. 2008 Sep;121(9):805–810.
Journal cover image

Published In

Am J Med

DOI

EISSN

1555-7162

Publication Date

September 2008

Volume

121

Issue

9

Start / End Page

805 / 810

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Risk
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Logistic Models
  • Incidence
  • Humans
  • Heparin